<HTML>
<HEAD>
<TITLE>sv8</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>As Filed with the Securities and Exchange Commission on October&nbsp;28, 2009</B>
</DIV>


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt; margin-top: 3pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM S-8</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 0pt"><B>REGISTRATION STATEMENT<BR>
Under<BR>
THE SECURITIES ACT OF 1933<BR>
<BR>
<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV></B>
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GLAXOSMITHKLINE PLC</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="47%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>England and Wales</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>98-0607772</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of <BR>
incorporation or organization)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>980 Great West Road<BR>
Brentford<BR>
Middlesex England<BR>
TW8 9GS</B><BR>
(Address of principal executive offices)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>GlaxoSmithKline Retirement Savings Plan<BR>
GSK Puerto Rico Retirement Savings Plan<BR>
GlaxoSmithKline 2009 Share Option Plan<BR>
GlaxoSmithKline 2009 Performance Share Plan<BR>
GlaxoSmithKline 2009 Share Value Plan<BR>
GSK Research &#038; Development Employee Inventor Award Programme</B><BR>
(Full title of the plans)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>William J. Mosher, Esquire<BR>
c/o GlaxoSmithKline LLC<BR>
One Franklin Plaza<BR>
P.O. Box 7929, FP2355<BR>
Philadelphia, PA 19101</B><BR>
(Name and address of agent for service)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(215)&nbsp;751-5046</B><BR>
(Telephone number, including area code, of agent for service)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated
filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act:
</DIV>

<TABLE width="100%" style="font-size: 10pt; margin-top: 6pt">
<TR valign="top"><TD>Large accelerated filer&nbsp;<FONT face="Wingdings">&#254;</FONT></TD>
<TD align="center">Accelerated filer&nbsp;<FONT face="Wingdings">&#111;</FONT>&nbsp;</TD>
<TD align="center">
Non-accelerated filer&nbsp;<FONT face="Wingdings">&#111;</FONT><BR>(Do not check if a smaller reporting company)</TD>
<TD align="right">Smaller reporting company&nbsp;<FONT face="Wingdings">&#111;</FONT></TD></TR></TABLE>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CALCULATION OF REGISTRATION FEE</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom" style="font-size: 1px">
    <TD width="1%">&nbsp;</TD>
    <TD width="54%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD><!-- VRule -->
    <TD width="2%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>

    <TD width="1%">&nbsp;</TD>
</TR><TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="23" style="border-bottom: 3px double #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Proposed</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Proposed</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">maximum</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center">Title of securities</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Amount to be</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">maximum offering</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">aggregate</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">Amount of</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">    <TD width="1%">&nbsp;</TD>

    <TD nowrap align="center">to be registered</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">registered (2)(3)</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">price per unit (4)</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">offering price(4)</TD>
    <TD style="border-right: 2px solid #000000">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3">registration fee(4)</TD>
    <TD width="1%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
                    <TD style="border-top: 2px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Ordinary Shares,
nominal value 25
pence</DIV></TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">2,464,786</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">18.49</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">45,573,893</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">2,543.02</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">per share
(&#147;Ordinary Shares&#148;)
(1)(5)</DIV></TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">247,135,214</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">20.25</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">5,004,488,084</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">279,250.44</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000"><DIV style="margin-left:15px; text-indent:-15px">Total</DIV></TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">249,600,000</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">5,050,061,977</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-right: 2px solid #000000; border-top: 2px solid #000000">&nbsp;</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD align="right" style="border-top: 2px solid #000000">$</TD>
    <TD align="right" style="border-top: 2px solid #000000">281,793.46</TD>
    <TD style="border-top: 2px solid #000000">&nbsp;</TD>
    <TD width="1%" style="border-top: 2px solid #000000">&nbsp;</TD>
</TR>
<TR style="font-size: 1px" valign="bottom">
    <TD nowrap align="left" colspan="23" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>

<!-- End Table Body -->
</TABLE>

</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 3pt">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">(1)</TD>
    <TD>&nbsp;</TD>
    <TD>American Depositary Receipts evidencing American Depositary Shares issuable on deposit of the
Ordinary Shares of GlaxoSmithKline plc (the &#147;Registrant&#148;) have been registered pursuant to a
separate Registration Statement on Form&nbsp;F-6 (No.&nbsp;333-148017) filed with the Commission on
December&nbsp;12, 2007. Each American Depositary Share represents two Ordinary Shares.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(2)</TD>
    <TD>&nbsp;</TD>
    <TD>This Registration Statement on Form S-8 (the &#147;Registration Statement&#148;) registers the issuance
of 249,600,000 ordinary shares, nominal value 25 pence per share (the &#147;Ordinary Shares&#148;) of
the Registrant, of which 45,000,000 are issuable pursuant to the GlaxoSmithKline 2009 Share
Option Plan, 12,500,000 are issuable pursuant to the GlaxoSmithKline 2009 Performance Share
Plan, 65,000,000 are issuable pursuant to the GlaxoSmithKline Retirement Savings Plan,
1,500,000 are issuable pursuant to the GSK Puerto Rico Retirement Savings Plan, 125,500,000
are issuable pursuant to the GlaxoSmithKline 2009 Share Value Plan and 100,000 are issuable
pursuant to the GSK Research &#038; Development Employee Inventor Award Programme (collectively,
the &#147;Plans&#148;).</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(3)</TD>
    <TD>&nbsp;</TD>
    <TD>This Registration Statement shall also cover any additional shares of Ordinary Shares which
become issuable under the Plans by reason of any stock dividend, stock split, recapitalization
or other similar transaction effected without receipt by the Registrant of consideration which
results in an increase in the number of outstanding shares of Registrant&#146;s Ordinary Shares.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(4)</TD>
    <TD>&nbsp;</TD>
    <TD>The Proposed Maximum Offering Price Per Share and the Proposed Maximum Aggregate Offering
Price are calculated in accordance with Rules 457(c) and (h)&nbsp;under the Securities Act of 1933,
as amended (the &#147;Securities Act&#148;), based on (i)&nbsp;the weighted average exercise price of $18.49
with respect to 2,464,786 Ordinary Shares (represented by a corresponding number of American
Depositary Shares) subject to stock options and restricted stock units awarded under the
GlaxoSmithKline 2009 Share Option Plan, GlaxoSmithKline 2009 Performance Share Plan and
GlaxoSmithKline 2009 Share Value Plan prior to the date of this Registration Statement, and
(ii)&nbsp;the average of the high and low sales prices of Ordinary Shares on the London Stock
Exchange on October&nbsp;23, 2009, using an exchange rate of $1.6340 per &#163; (as reported in the
online edition of the Financial Times dated October&nbsp;23, 2009), and are being utilized solely
for the purpose of calculating the registration fee.</TD>
</TR>

<TR style="font-size: 3pt"><TD>&nbsp;</TD></TR>

<TR valign="top">
    <TD nowrap align="left">(5)</TD>
    <TD>&nbsp;</TD>
    <TD>In addition, pursuant to Rule 416(c) under the Securities Act, this Registration Statement
also covers an indeterminate amount of interests to be offered or sold pursuant to the
GlaxoSmithKline Retirement Savings Plan or the GSK Puerto Rico Retirement Savings Plan.</TD>
</TR>

</TABLE>



<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<DIV style="font-family: Helvetica,Arial,sans-serif">





<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000"><U>Part I </U><BR> <U>Information Required in the Section&nbsp;10(a) Prospectus</U></A></TD></TR>
<TR><TD colspan="9"><A HREF="#001"><U>Part II </U><BR> <U>Information Required in the Registration Statement</U></A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#002"><B>Item&nbsp;3. Incorporation of Documents by Reference.</B></A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#003">Item&nbsp;4. Description of Securities</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#004">Item&nbsp;5. Interests of Named Experts and Counsel</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#005">Item&nbsp;6. Indemnification of Directors and Officers</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#006">Item&nbsp;7. Exemption From Registration Claimed</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#007">Item&nbsp;8. Exhibits.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#008">Item&nbsp;9 Undertakings.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#009">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#010">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w3.htm">EX-4.3</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w4.htm">EX-4.4</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w5.htm">EX-4.5</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w7.htm">EX-4.7</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w8.htm">EX-4.8</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w9.htm">EX-4.9</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w10.htm">EX-4.10</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w11.htm">EX-4.11</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w12.htm">EX-4.12</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv4w13.htm">EX-4.13</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv5w1.htm">EX-5.1</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv5w2.htm">EX-5.2</A></TD></TR>
<TR><TD colspan="9"><A HREF="w76040exv23w1.htm">EX-23.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXPLANATORY NOTE</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">As a result of the consummation on December&nbsp;27, 2000 of the merger transaction between Glaxo
Wellcome plc (&#147;GW&#148;) and SmithKline Beecham plc (&#147;SB&#148;), GlaxoSmithKline plc (the &#147;Registrant&#148;)
acquired GW and SB. The Registrant subsequently filed with the Securities and Exchange Commission
(the &#147;Commission&#148;) Form&nbsp;S-8 (No.&nbsp;333-13022) to register shares previously covered by then-effective
GW and SB equity compensation plans, including the GlaxoSmithKline Retirement Savings Plan (the
&#147;Retirement Savings Plan&#148;), formerly known as the SmithKline Beecham Retirement Savings Plan, and
the GSK Puerto Rico Retirement Savings Plan (the &#147;Puerto Rico Retirement Savings Plan&#148;), formerly
known as the SB Puerto Rico Retirement Savings Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to General Instruction E of Form S-8, this registration statement on Form S-8 (the
&#147;Registration Statement&#148;) is being filed in order to register an additional 65,000,000 shares of
the Registrant&#146;s Ordinary Shares, which are securities of the same class and relate to the same
employee benefit plan, the Retirement
Savings Plan, as those shares registered on the Registrant&#146;s registration statement on Form S-8
previously filed with the Commission on December&nbsp;27, 2000 (Registration No.&nbsp;333-13022), which is
hereby incorporated by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to General Instruction E of Form S-8, this Registration Statement is also being filed in
order to register an additional 1,500,000 shares of the Registrant&#146;s Ordinary Shares, which are
securities of the same class and relate to the same employee benefit plan, the Puerto Rico
Retirement Savings Plan, as those shares registered on the Registrant&#146;s registration statement on
Form S-8 previously filed with the Commission on December&nbsp;27, 2000 (Registration No.&nbsp;333-13022),
which is hereby incorporated by reference.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Registration Statement is also being filed in order to register 45,000,000 shares of the
Registrant&#146;s Ordinary Shares issuable under the GlaxoSmithKline 2009 Share Option Plan (the &#147;Share
Option Plan&#148;), 12,500,000 shares issuable under the GlaxoSmithKline 2009 Performance Share Plan
(the &#147;Performance Share Plan&#148;), 125,500,000 shares issuable under the GlaxoSmithKline 2009 Share
Value Plan (the &#147;Share Value Plan&#148;) and 100,000 shares issuable under the GSK Research &#038;
Development Employee Inventor Award Programme (the &#147;Inventor Award Programme&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Registration Statement is also being filed in order to file, as exhibits, certain amendments
to the Retirement Savings Plan and Puerto Rico Retirement Savings Plan.
</DIV>

<!-- link1 "<U>Part I </U><BR> <U>Information Required in the Section&nbsp;10(a) Prospectus</U>" -->
<DIV align="left"><A NAME="000"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Part I </B></U><BR>
<U><B>Information Required in the Section&nbsp;10(a) Prospectus</B></U>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Information required by Part&nbsp;I to be contained in the Section 10(a) prospectus is omitted from this
Registration Statement in accordance with Rule&nbsp;428 under the Securities Act, and the &#147;Note&#148; to Part
I of Form S-8.
</DIV>

<!-- link1 "<U>Part II </U><BR> <U>Information Required in the Registration Statement</U>" -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Part II </B></U><BR>
<U><B>Information Required in the Registration Statement</B></U>
</DIV>


<!-- link2 "<B>Item&nbsp;3. Incorporation of Documents by Reference.</B>" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;3. Incorporation of Documents by Reference.</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The following documents previously filed by Registrant with the Commission are hereby incorporated
by reference to this registration statement:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(a)&nbsp;The Registrant&#146;s Annual Report on Form 20-F for the fiscal year ended December&nbsp;31, 2008
(the &#147;2008 Annual Report&#148;).
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">All documents filed by the Registrant pursuant to Sections&nbsp;13(a), 13(c), 14 and 15(d) of the
Securities Exchange Act of 1934, as amended (&#147;Exchange Act&#148;) subsequent to the effective date of
this Registration Statement, but prior to the filing of a post-effective amendment to this
Registration Statement indicating that all securities offered hereby have been sold or
de-registering all securities then remaining unsold, shall be deemed to be incorporated by
reference herein and to be a part hereof from the date of filing of such documents.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Any statement contained herein or in any document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded for purposes of this Registration
Statement to the extent that a statement contained herein or in any other subsequently filed
document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed to constitute a
part of this Registration Statement, except as so modified or superseded.
</DIV>

<!-- link2 "Item&nbsp;4. Description of Securities" -->
<DIV align="left"><A NAME="003"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;4. Description of Securities</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The securities registered by this Registration Statement are Registrant&#146;s Ordinary Shares, nominal
value 25 pence, which are listed on the London Stock Exchange. The Ordinary Shares registered by
this Registration Statement may be purchased only through exercise of Options granted under the
Plans.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(a)&nbsp;Dividend Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of Ordinary Shares are entitled to dividends when declared by Registrant&#146;s Board of
Directors (&#147;Directors&#148;) or by resolution of Registrant&#146;s shareholders. Dividends may be paid in
whatever currency chosen by the Directors. Dividends are generally paid pro rata according to the
amounts paid up on each Share during the period in respect of which the dividends are paid.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon approval by the Directors and Registrant&#146;s shareholders, specific assets held by
Registrant may be paid as dividends. Upon approval of the holders of Ordinary Shares by ordinary
resolution, the Directors can offer shareholders the ability to receive cash dividends in cash or
in Ordinary Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends must be paid out of Registrant&#146;s profits available for distribution. Registrant may
deduct any amounts owed to Registrant from a holder of Ordinary Shares relating to such Shares (for
example, for unpaid calls as outlined below) from any dividends due to such holder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Directors may withhold payment of dividends to any holder of 0.25&nbsp;percent or more of the
existing Ordinary Shares who has not provided information concerning the holder&#146;s interests in his
or her Shares as required by the United Kingdom Companies Act 2006 (&#147;Companies Act&#148;) for a period
of fourteen days.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends unclaimed for 12&nbsp;years after authorized by Registrant will be forfeited.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(b)&nbsp;Voting Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Ordinary Share receives one vote. Votes may be entered by the shareholder or via proxy.
&#147;Ordinary resolutions&#148; under consideration at general meetings of Registrant&#146;s shareholders are
decided by simple majority vote of the shareholders entitled to vote at such meeting.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A &#147;special resolution&#148; requires an affirmative vote of at least 75% of the votes cast. The
notice must describe the vote as being subject to passage by special resolution.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the Directors decide otherwise, holders of Ordinary Shares that have not paid all calls
and sums payable to Registrant relating to any Shares may not vote those Shares. Additionally, any
holder who has
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">not provided information concerning the holder&#146;s interests in his or her Shares as
required by the Companies Act for a period of fourteen days may not vote any shares of Registrant,
unless decided otherwise by the Directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To modify the rights granted to Ordinary Shares, either:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>the written consent of three-quarters in nominal value of the issued Ordinary
Shares is required; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>a special resolution must be passed at a separate meeting of all holders of Ordinary Shares.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of Ordinary Shares may, by ordinary resolution:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Increase Registrant&#146;s share capital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consolidate and divide all or any of Registrant&#146;s shares into shares of a
larger nominal amount;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Cancel any shares not taken or agreed to be taken by any person;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Subdivide Registrant&#146;s shares into shares of a smaller nominal amount;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Vary the maximum or minimum number of Directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Elect, remove and appoint replacement Directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Specify the allocation of fees paid to the Directors for their services as Directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Authorize the Directors to offer holders of Ordinary Shares the right to
choose to receive new Ordinary Shares instead of their cash dividends;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Declare dividends on Ordinary Shares, but such dividends may not exceed the
amount recommended by the Directors;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Divide among Registrant&#146;s shareholders all or any part of the specific assets
of the Registrant; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Upon recommendation of the Directors, direct that dividends be paid on
Ordinary Shares by distributing specific assets of Registrant.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of Ordinary Shares may, by special resolution:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Empower a liquidator to divide all or part of the Registrant&#146;s specific assets
among such holders of Ordinary Shares as the liquidator deems fair;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Reduce Registrant&#146;s share capital;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Reduce any capital redemption reserve (a reserve of funds which Registrant may
have set up to keep its capital base when shares are repurchased by Registrant);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Reduce any share premium account (a reserve account established and funded by
amounts paid above the nominal value of Registrant&#146;s shares);</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Reduce other undistributable reserves; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Regulate the management of Registrant&#146;s business by the Directors.</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(c)&nbsp;Classification of Directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Directors are divided into two classes, executive directors and non-executive directors.
Executive directors are also full-time employees of Registrant, while non-executive directors are
not so employed. There is no other difference between executive directors and non-executive
directors.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(d)&nbsp;Liquidation Rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of Ordinary Shares may participate in any surplus assets in a winding-up in
proportion to their holdings of Ordinary Shares. If approved by special resolution of the holders
of Ordinary Shares, a liquidator may divide all or part of the Registrant&#146;s specific assets among
such holders as the liquidator deems fair.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(e)&nbsp;Liabilities for Calls and Assessments.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Directors may call on Registrant&#146;s shareholders to pay any money which has not been paid
to Registrant for their shares. Failure to pay amounts called:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>results in a first-priority lien in favor of the Registrant upon the Shares;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>may result in forfeiture of the Shares if the Directors decide to sell the
Shares to enforce the lien fourteen days after written notice to the holder;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>may result in forfeiture of voting rights as outlined in (b)&nbsp;above; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>may result in forfeiture of the shares after written notice.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If dividends are declared on any Shares which have not been fully paid, the dividends may be
reduced by the amount of the call outstanding, as outlined in (a)&nbsp;above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Ordinary Shares registered by this Registration Statement are not subject to any call
rights beyond the purchaser&#146;s obligation to pay the initial acquisition price of the Ordinary
Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(f)&nbsp;Restrictions on Alienation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fully-paid Ordinary Shares evidenced by certificates may be transferred in any usual form or
another form approved by the Directors. Ordinary Shares which are not fully paid are subject to a
first-priority lien in favor of the Registrant and the Directors may decline to transfer any such
Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Directors may also decline any transfer which is:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="5%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>in favor of five or more transferees;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>concerns more than one class of Registrant&#146;s shares on a single transfer form; or</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>requested by a holder who has not provided information concerning the holder&#146;s
interests in his or her Shares as required by the Companies Act.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Directors may suspend registration of transfers at any time but the suspensions may not
exceed 30&nbsp;days in any year.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(g)&nbsp;Unequal Treatment of Substantial Shareholders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Directors may withhold payment of dividends to any holder of 0.25&nbsp;percent or more of the
existing Ordinary Shares who has not provided information concerning the holder&#146;s interests in his
or her Shares as required by the Companies Act for a period of fourteen days as outlined in (a)
above. Furthermore, the holder is not entitled to receive shares of Registrant in lieu of the
dividends. Lastly, the Directors may also decline to transfer any Shares of such holder as outlined
in (f)&nbsp;above.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(h)&nbsp;Ownership and Voting Limitations on Non-Resident Owners.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no limitations relating only to non-residents of the United Kingdom under English
law or the Registrant&#146;s Memorandum and Articles of Association on the right to be a holder of, and
to vote in respect of, Registrant&#146;s Ordinary Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(i)&nbsp;United Kingdom Laws Affecting Dividends Paid to Non-Residents.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are currently no United Kingdom laws, decrees or regulations affecting the remittance of
dividends or other payments to holders of Registrant&#146;s Ordinary Shares who are non-residents of the
United Kingdom, except as outlined in (k)&nbsp;below.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(j)&nbsp;United Kingdom Tax Effects on United States Owners.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United Kingdom taxes will be assessed and withheld from participants who are considered United
States residents (&#147;U.S. Participants&#148;). U.S. Participants are generally not subject to United
Kingdom capital gains tax or United Kingdom inheritance tax.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A sale of Ordinary Shares by a U.S. Participant is subject to United Kingdom stamp duty, or
stamp duty reserve tax (&#147;SDRT&#148;), as applicable. The minimum stamp duty liability is five pounds
Sterling (L5). Currently, SDRT is assessed at a rate of 0.5% of the purchase price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">(k)&nbsp;Reciprocal Tax Treaties Affecting Withholding.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None.
</DIV>

<!-- link2 "Item&nbsp;5. Interests of Named Experts and Counsel" -->
<DIV align="left"><A NAME="004"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;5. Interests of Named Experts and Counsel</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">None.
</DIV>

<!-- link2 "Item&nbsp;6. Indemnification of Directors and Officers" -->
<DIV align="left"><A NAME="005"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;6. Indemnification of Directors and Officers</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">English law does not permit a company to indemnify a director or an officer of the company against
any liability which by virtue of any rule of law would otherwise attach to him in respect of
negligence, default, breach of duty or breach of trust in relation to the company. However, English
law does permit a company to purchase insurance for its directors and officers against such
liabilities. In addition, a company may exempt or indemnity a director or officer against any
liability to a third party, or indemnify a director or officer acting as a trustee of an
occupational pension scheme against liability incurred in connection with the company&#146;s activities
as trustee of the scheme, but only in the event that such liability is incurred by such director or
officer in defending any legal proceeding (whether civil or criminal) in which judgment is given in
his favor or in which
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">he is acquitted or in certain instances where, although he is liable, a court
finds such director or officer acted honestly and reasonably and that having regard to all the
circumstances he ought fairly to be excused and relief is granted by the court.
</DIV>

<!-- link2 "Item&nbsp;7. Exemption From Registration Claimed" -->
<DIV align="left"><A NAME="006"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;7. Exemption From Registration Claimed</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Not applicable.
</DIV>

<!-- link2 "Item&nbsp;8. Exhibits." -->
<DIV align="left"><A NAME="007"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8. Exhibits.</B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">3.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Memorandum and Articles of Association of GlaxoSmithKline plc
(incorporated by reference to Exhibit&nbsp;No.&nbsp;1.1 of the Annual Report on Form 20-F
of GlaxoSmithKline plc, for the year ended December&nbsp;31, 2008).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Deposit Agreement among GlaxoSmithKline plc and The Bank of New
York, as Depositary, and the holders from time to time of the American Depositary
Receipts issued thereunder, including the form of American Depositary Receipt
(incorporated by reference to Registration Statement on Form F-6, Registration
No.&nbsp;333-148017).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GlaxoSmithKline Retirement Savings Plan (incorporated by reference
to Exhibit&nbsp;No.&nbsp;4.6 of the Registration Statement of GlaxoSmithKline plc on Form
S-8, Registration No.&nbsp;333-13022).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.3</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amendment No.&nbsp;1 to GlaxoSmithKline Retirement Savings Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.4</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amendment No.&nbsp;2 to GlaxoSmithKline Retirement Savings Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.5</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amendment No.&nbsp;3 to GlaxoSmithKline Retirement Savings Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.6</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GSK Puerto Rico Retirement Savings Plan (incorporated by reference
to Exhibit&nbsp;No.&nbsp;4.9 of the Registration Statement of GlaxoSmithKline plc on Form
S-8, Registration No.&nbsp;333-13022).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.7</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amendment No.&nbsp;1 to GSK Puerto Rico Retirement Savings Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.8</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amendment No.&nbsp;2 to GSK Puerto Rico Retirement Savings Plan.</TD>
</TR>


<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.9</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amendment No.&nbsp;3 to GSK Puerto Rico Retirement Savings Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.10</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GlaxoSmithKline 2009 Share Option Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.11</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GlaxoSmithKline 2009 Performance Share Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.12</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GlaxoSmithKline 2009 Share Value Plan.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">4.13</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>GSK Research &#038; Development Employee Inventor Award Programme</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Opinion of Linklaters.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">5.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Opinion of Pepper Hamilton LLP.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">23.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consent of PricewaterhouseCoopers (filed herewith).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">23.2</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Consent of Linklaters (contained in Exhibit&nbsp;5.1).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">24.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Power of Attorney (contained in the signature pages hereto).</TD>
</TR>

</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>
<!-- link2 "Item&nbsp;9 Undertakings." -->
<DIV align="left"><A NAME="008"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9 Undertakings.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Item&nbsp;512(a) of Regulation&nbsp;S-K</U>

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned Registrant hereby undertakes:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)&nbsp;To file, during any period in which offers or sales are being made, a post-effective
amendment to this Registration Statement:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of
1933, as amended (the &#147;Securities Act&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date
of the registration statement (or the most recent post-effective amendment thereof) which,
individually or in
the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20%
change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration
Fee&#148; table in the effective registration statement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not
previously disclosed in this Registration Statement or any material change to such
information in this Registration Statement;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>provided</U>, <U>however</U>, that paragraphs (1)(i) and (1)(ii) above do not apply if
the information required to be included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the Commission by the Registrant pursuant to
Section&nbsp;13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration
Statement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)&nbsp;That, for the purpose of determining any liability under the Securities Act each such
post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)&nbsp;To remove from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of the offering.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Item&nbsp;512(b) of Regulation&nbsp;S-K</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned Registrant hereby undertakes that, for purposes of determining any liability
under the Securities Act each filing of the Registrant&#146;s annual report pursuant to Section 13(a) or
Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s
annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in
the registration statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U>Item&nbsp;512(h) of Regulation&nbsp;S-K.</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Registrant pursuant to the foregoing
provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered,
the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">



<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="009"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the Commonwealth of Pennsylvania, on October&nbsp;28, 2009.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>GLAXOSMITHKLINE PLC</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" style="border-bottom: 1px solid #000000" align="left">/s/ William J. Mosher
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">William J. Mosher, Authorized U.S. Representative&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD colspan="3" align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>POWER OF ATTORNEY</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes
and appoints William J. Mosher, Victoria A. Whyte and Justin T. Huang (with full power to each of
them to act alone) his or her true and lawful attorney-in-fact and agent, with full power of
substitution and resubstitution, for him or her and in his or her name, place and stead, in any and
all capacities, to sign any and all amendments (including post-effective amendments) to this
registration statement, and to file the same, with exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and every act and thing
requisite and necessary to be done, as fully to all intents and purposes as he or she might or
could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or
either of them, or their or his or her substitute or substitutes, may lawfully do or cause to be
done by virtue hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been
signed below by the following persons in the capacities and on the dates indicated.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Signature</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Title</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Date</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Sir Christopher Gent
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chairman; Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sir Christopher Gent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Andrew Witty
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chief Executive Officer; Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Andrew Witty</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Professor Sir Roy Anderson
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Professor Sir Roy Anderson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Signature</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Title</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Date</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Dr.&nbsp;Stephanie Burns
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dr. Stephanie Burns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Lawrence Culp
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lawrence Culp</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Sir Crispin Davis
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sir Crispin Davis</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Tom de Swaan
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tom de Swaan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Julian Heslop
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chief Financial Officer; Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Julian Heslop</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Sir Deryck Maughan
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sir Deryck Maughan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ James Murdoch
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">James Murdoch</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Dr.&nbsp;Daniel Podolsky
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dr. Daniel Podolsky</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Dr.&nbsp;Moncef Slaoui
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Chairman Research &#038; Development;

</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dr. Moncef Slaoui</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Sir Robert Wilson
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Director&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">October&nbsp;1, 2009</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sir Robert Wilson</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: Helvetica,Arial,sans-serif">

<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="010"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>EXHIBIT INDEX</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left">Exhibit</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">Exhibit</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Number</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.3
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment No.&nbsp;1 to GlaxoSmithKline Retirement Savings Plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.4
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment No.&nbsp;2 to GlaxoSmithKline Retirement Savings Plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.5
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment No.&nbsp;3 to GlaxoSmithKline Retirement Savings Plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment No.&nbsp;1 to GSK Puerto Rico Retirement Savings Plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.8
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment No.&nbsp;2 to GSK Puerto Rico Retirement Savings Plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.9
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Amendment No.&nbsp;3 to GSK Puerto Rico Retirement Savings Plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.10
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GlaxoSmithKline 2009 Share Option Plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.11
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GlaxoSmithKline 2009 Performance Share Plan .</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.12
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GlaxoSmithKline 2009 Share Value Plan.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">4.13
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">GSK Research &#038; Development Employee Inventor Award Programme</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">5.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Linklaters.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">5.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Opinion of Pepper Hamilton LLP.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">23.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Pricewaterhouse Coopers LLP.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">23.2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Consent of Linklaters (contained in Exhibit&nbsp;5.1).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top"><DIV style="margin-left:30px; text-indent:-15px">24.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Power of Attorney (contained in the signature pages hereto).</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "w76040sv8.htm", "description": "FORM S-8", "secsgml_size_bytes": 90670}]
{"company-data": {"conformed-name": "GLAXOSMITHKLINE PLC", "cik": "0001131399", "assigned-sic": "2834", "irs-number": "000000000"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-162702", "film-number": "091141026"}, "business-address": {"street1": "980 GREAT WEST ROAD", "city": "BRENTFORD MIDDLESEX", "state": "X0", "zip": "TW8 9GS", "phone": "011442080475000"}, "mail-address": {"street1": "980 GREAT WEST ROAD", "city": "BRENTFORD MIDDLESEX", "state": "X0", "zip": "TW8 9GS"}}
sv8
Table of Contents
As Filed with the Securities and Exchange Commission on October 28, 2009
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
Under
THE SECURITIES ACT OF 1933
GLAXOSMITHKLINE PLC
(Exact name of registrant as specified in charter)
England and Wales
98-0607772
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer Identification No.)
980 Great West Road
Brentford
Middlesex England
TW8 9GS
(Address of principal executive offices)
GlaxoSmithKline Retirement Savings Plan
GSK Puerto Rico Retirement Savings Plan
GlaxoSmithKline 2009 Share Option Plan
GlaxoSmithKline 2009 Performance Share Plan
GlaxoSmithKline 2009 Share Value Plan
GSK Research & Development Employee Inventor Award Programme
(Full title of the plans)
William J. Mosher, Esquire
c/o GlaxoSmithKline LLC
One Franklin Plaza
P.O. Box 7929, FP2355
Philadelphia, PA 19101
(Name and address of agent for service)
(215) 751-5046
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated
filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act:
Large accelerated filer
þ
Accelerated filer
o
Non-accelerated filer
o
(Do not check if a smaller reporting company)
Smaller reporting company
o
CALCULATION OF REGISTRATION FEE
Proposed
Proposed
maximum
Title of securities
Amount to be
maximum offering
aggregate
Amount of
to be registered
registered (2)(3)
price per unit (4)
offering price(4)
registration fee(4)
Ordinary Shares,
nominal value 25
pence
2,464,786
$
18.49
$
45,573,893
$
2,543.02
per share
("Ordinary Shares")
(1)(5)
247,135,214
$
20.25
$
5,004,488,084
$
279,250.44
Total
249,600,000
$
5,050,061,977
$
281,793.46
(1)
American Depositary Receipts evidencing American Depositary Shares issuable on deposit of the
Ordinary Shares of GlaxoSmithKline plc (the "Registrant") have been registered pursuant to a
separate Registration Statement on Form F-6 (No. 333-148017) filed with the Commission on
December 12, 2007. Each American Depositary Share represents two Ordinary Shares.
(2)
This Registration Statement on Form S-8 (the "Registration Statement") registers the issuance
of 249,600,000 ordinary shares, nominal value 25 pence per share (the "Ordinary Shares") of
the Registrant, of which 45,000,000 are issuable pursuant to the GlaxoSmithKline 2009 Share
Option Plan, 12,500,000 are issuable pursuant to the GlaxoSmithKline 2009 Performance Share
Plan, 65,000,000 are issuable pursuant to the GlaxoSmithKline Retirement Savings Plan,
1,500,000 are issuable pursuant to the GSK Puerto Rico Retirement Savings Plan, 125,500,000
are issuable pursuant to the GlaxoSmithKline 2009 Share Value Plan and 100,000 are issuable
pursuant to the GSK Research & Development Employee Inventor Award Programme (collectively,
the "Plans").
(3)
This Registration Statement shall also cover any additional shares of Ordinary Shares which
become issuable under the Plans by reason of any stock dividend, stock split, recapitalization
or other similar transaction effected without receipt by the Registrant of consideration which
results in an increase in the number of outstanding shares of Registrant's Ordinary Shares.
(4)
The Proposed Maximum Offering Price Per Share and the Proposed Maximum Aggregate Offering
Price are calculated in accordance with Rules 457(c) and (h) under the Securities Act of 1933,
as amended (the "Securities Act"), based on (i) the weighted average exercise price of $18.49
with respect to 2,464,786 Ordinary Shares (represented by a corresponding number of American
Depositary Shares) subject to stock options and restricted stock units awarded under the
GlaxoSmithKline 2009 Share Option Plan, GlaxoSmithKline 2009 Performance Share Plan and
GlaxoSmithKline 2009 Share Value Plan prior to the date of this Registration Statement, and
(ii) the average of the high and low sales prices of Ordinary Shares on the London Stock
Exchange on October 23, 2009, using an exchange rate of $1.6340 per £ (as reported in the
online edition of the Financial Times dated October 23, 2009), and are being utilized solely
for the purpose of calculating the registration fee.
(5)
In addition, pursuant to Rule 416(c) under the Securities Act, this Registration Statement
also covers an indeterminate amount of interests to be offered or sold pursuant to the
GlaxoSmithKline Retirement Savings Plan or the GSK Puerto Rico Retirement Savings Plan.
TABLE OF CONTENTS
Part I
Information Required in the Section 10(a) Prospectus
Part II
Information Required in the Registration Statement
Item 3. Incorporation of Documents by Reference.
Item 4. Description of Securities
Item 5. Interests of Named Experts and Counsel
Item 6. Indemnification of Directors and Officers
Item 7. Exemption From Registration Claimed
Item 8. Exhibits.
Item 9 Undertakings.
SIGNATURES
EXHIBIT INDEX
EX-4.3
EX-4.4
EX-4.5
EX-4.7
EX-4.8
EX-4.9
EX-4.10
EX-4.11
EX-4.12
EX-4.13
EX-5.1
EX-5.2
EX-23.1
Table of Contents
EXPLANATORY NOTE
As a result of the consummation on December 27, 2000 of the merger transaction between Glaxo
Wellcome plc ("GW") and SmithKline Beecham plc ("SB"), GlaxoSmithKline plc (the "Registrant")
acquired GW and SB. The Registrant subsequently filed with the Securities and Exchange Commission
(the "Commission") Form S-8 (No. 333-13022) to register shares previously covered by then-effective
GW and SB equity compensation plans, including the GlaxoSmithKline Retirement Savings Plan (the
"Retirement Savings Plan"), formerly known as the SmithKline Beecham Retirement Savings Plan, and
the GSK Puerto Rico Retirement Savings Plan (the "Puerto Rico Retirement Savings Plan"), formerly
known as the SB Puerto Rico Retirement Savings Plan.
Pursuant to General Instruction E of Form S-8, this registration statement on Form S-8 (the
"Registration Statement") is being filed in order to register an additional 65,000,000 shares of
the Registrant's Ordinary Shares, which are securities of the same class and relate to the same
employee benefit plan, the Retirement
Savings Plan, as those shares registered on the Registrant's registration statement on Form S-8
previously filed with the Commission on December 27, 2000 (Registration No. 333-13022), which is
hereby incorporated by reference.
Pursuant to General Instruction E of Form S-8, this Registration Statement is also being filed in
order to register an additional 1,500,000 shares of the Registrant's Ordinary Shares, which are
securities of the same class and relate to the same employee benefit plan, the Puerto Rico
Retirement Savings Plan, as those shares registered on the Registrant's registration statement on
Form S-8 previously filed with the Commission on December 27, 2000 (Registration No. 333-13022),
which is hereby incorporated by reference.
This Registration Statement is also being filed in order to register 45,000,000 shares of the
Registrant's Ordinary Shares issuable under the GlaxoSmithKline 2009 Share Option Plan (the "Share
Option Plan"), 12,500,000 shares issuable under the GlaxoSmithKline 2009 Performance Share Plan
(the "Performance Share Plan"), 125,500,000 shares issuable under the GlaxoSmithKline 2009 Share
Value Plan (the "Share Value Plan") and 100,000 shares issuable under the GSK Research &
Development Employee Inventor Award Programme (the "Inventor Award Programme").
This Registration Statement is also being filed in order to file, as exhibits, certain amendments
to the Retirement Savings Plan and Puerto Rico Retirement Savings Plan.
Part I
Information Required in the Section 10(a) Prospectus
Information required by Part I to be contained in the Section 10(a) prospectus is omitted from this
Registration Statement in accordance with Rule 428 under the Securities Act, and the "Note" to Part
I of Form S-8.
Part II
Information Required in the Registration Statement
Item 3. Incorporation of Documents by Reference.
The following documents previously filed by Registrant with the Commission are hereby incorporated
by reference to this registration statement:
(a) The Registrant's Annual Report on Form 20-F for the fiscal year ended December 31, 2008
(the "2008 Annual Report").
All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the
Securities Exchange Act of 1934, as amended ("Exchange Act") subsequent to the effective date of
this Registration Statement, but prior to the filing of a post-effective amendment to this
Registration Statement indicating that all securities offered hereby have been sold or
de-registering all securities then remaining unsold, shall be deemed to be incorporated by
reference herein and to be a part hereof from the date of filing of such documents.
Table of Contents
Any statement contained herein or in any document incorporated or deemed to be incorporated by
reference herein shall be deemed to be modified or superseded for purposes of this Registration
Statement to the extent that a statement contained herein or in any other subsequently filed
document which also is or is deemed to be incorporated by reference herein modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed to constitute a
part of this Registration Statement, except as so modified or superseded.
Item 4. Description of Securities
The securities registered by this Registration Statement are Registrant's Ordinary Shares, nominal
value 25 pence, which are listed on the London Stock Exchange. The Ordinary Shares registered by
this Registration Statement may be purchased only through exercise of Options granted under the
Plans.
(a) Dividend Rights.
Holders of Ordinary Shares are entitled to dividends when declared by Registrant's Board of
Directors ("Directors") or by resolution of Registrant's shareholders. Dividends may be paid in
whatever currency chosen by the Directors. Dividends are generally paid pro rata according to the
amounts paid up on each Share during the period in respect of which the dividends are paid.
Upon approval by the Directors and Registrant's shareholders, specific assets held by
Registrant may be paid as dividends. Upon approval of the holders of Ordinary Shares by ordinary
resolution, the Directors can offer shareholders the ability to receive cash dividends in cash or
in Ordinary Shares.
Dividends must be paid out of Registrant's profits available for distribution. Registrant may
deduct any amounts owed to Registrant from a holder of Ordinary Shares relating to such Shares (for
example, for unpaid calls as outlined below) from any dividends due to such holder.
The Directors may withhold payment of dividends to any holder of 0.25 percent or more of the
existing Ordinary Shares who has not provided information concerning the holder's interests in his
or her Shares as required by the United Kingdom Companies Act 2006 ("Companies Act") for a period
of fourteen days.
Dividends unclaimed for 12 years after authorized by Registrant will be forfeited.
(b) Voting Rights.
Each Ordinary Share receives one vote. Votes may be entered by the shareholder or via proxy.
"Ordinary resolutions" under consideration at general meetings of Registrant's shareholders are
decided by simple majority vote of the shareholders entitled to vote at such meeting.
A "special resolution" requires an affirmative vote of at least 75% of the votes cast. The
notice must describe the vote as being subject to passage by special resolution.
Unless the Directors decide otherwise, holders of Ordinary Shares that have not paid all calls
and sums payable to Registrant relating to any Shares may not vote those Shares. Additionally, any
holder who has
Table of Contents
not provided information concerning the holder's interests in his or her Shares as
required by the Companies Act for a period of fourteen days may not vote any shares of Registrant,
unless decided otherwise by the Directors.
To modify the rights granted to Ordinary Shares, either:
•
the written consent of three-quarters in nominal value of the issued Ordinary
Shares is required; or
•
a special resolution must be passed at a separate meeting of all holders of Ordinary Shares.
The holders of Ordinary Shares may, by ordinary resolution:
•
Increase Registrant's share capital;
•
Consolidate and divide all or any of Registrant's shares into shares of a
larger nominal amount;
•
Cancel any shares not taken or agreed to be taken by any person;
•
Subdivide Registrant's shares into shares of a smaller nominal amount;
•
Vary the maximum or minimum number of Directors;
•
Elect, remove and appoint replacement Directors;
•
Specify the allocation of fees paid to the Directors for their services as Directors;
•
Authorize the Directors to offer holders of Ordinary Shares the right to
choose to receive new Ordinary Shares instead of their cash dividends;
•
Declare dividends on Ordinary Shares, but such dividends may not exceed the
amount recommended by the Directors;
•
Divide among Registrant's shareholders all or any part of the specific assets
of the Registrant; or
•
Upon recommendation of the Directors, direct that dividends be paid on
Ordinary Shares by distributing specific assets of Registrant.
The holders of Ordinary Shares may, by special resolution:
•
Empower a liquidator to divide all or part of the Registrant's specific assets
among such holders of Ordinary Shares as the liquidator deems fair;
•
Reduce Registrant's share capital;
•
Reduce any capital redemption reserve (a reserve of funds which Registrant may
have set up to keep its capital base when shares are repurchased by Registrant);
•
Reduce any share premium account (a reserve account established and funded by
amounts paid above the nominal value of Registrant's shares);
•
Reduce other undistributable reserves; or
•
Regulate the management of Registrant's business by the Directors.
Table of Contents
(c) Classification of Directors.
The Directors are divided into two classes, executive directors and non-executive directors.
Executive directors are also full-time employees of Registrant, while non-executive directors are
not so employed. There is no other difference between executive directors and non-executive
directors.
(d) Liquidation Rights.
The holders of Ordinary Shares may participate in any surplus assets in a winding-up in
proportion to their holdings of Ordinary Shares. If approved by special resolution of the holders
of Ordinary Shares, a liquidator may divide all or part of the Registrant's specific assets among
such holders as the liquidator deems fair.
(e) Liabilities for Calls and Assessments.
The Directors may call on Registrant's shareholders to pay any money which has not been paid
to Registrant for their shares. Failure to pay amounts called:
•
results in a first-priority lien in favor of the Registrant upon the Shares;
•
may result in forfeiture of the Shares if the Directors decide to sell the
Shares to enforce the lien fourteen days after written notice to the holder;
•
may result in forfeiture of voting rights as outlined in (b) above; and
•
may result in forfeiture of the shares after written notice.
If dividends are declared on any Shares which have not been fully paid, the dividends may be
reduced by the amount of the call outstanding, as outlined in (a) above.
The Ordinary Shares registered by this Registration Statement are not subject to any call
rights beyond the purchaser's obligation to pay the initial acquisition price of the Ordinary
Shares.
(f) Restrictions on Alienation.
Fully-paid Ordinary Shares evidenced by certificates may be transferred in any usual form or
another form approved by the Directors. Ordinary Shares which are not fully paid are subject to a
first-priority lien in favor of the Registrant and the Directors may decline to transfer any such
Shares.
The Directors may also decline any transfer which is:
•
in favor of five or more transferees;
•
concerns more than one class of Registrant's shares on a single transfer form; or
•
requested by a holder who has not provided information concerning the holder's
interests in his or her Shares as required by the Companies Act.
The Directors may suspend registration of transfers at any time but the suspensions may not
exceed 30 days in any year.
Table of Contents
(g) Unequal Treatment of Substantial Shareholders.
The Directors may withhold payment of dividends to any holder of 0.25 percent or more of the
existing Ordinary Shares who has not provided information concerning the holder's interests in his
or her Shares as required by the Companies Act for a period of fourteen days as outlined in (a)
above. Furthermore, the holder is not entitled to receive shares of Registrant in lieu of the
dividends. Lastly, the Directors may also decline to transfer any Shares of such holder as outlined
in (f) above.
(h) Ownership and Voting Limitations on Non-Resident Owners.
There are no limitations relating only to non-residents of the United Kingdom under English
law or the Registrant's Memorandum and Articles of Association on the right to be a holder of, and
to vote in respect of, Registrant's Ordinary Shares.
(i) United Kingdom Laws Affecting Dividends Paid to Non-Residents.
There are currently no United Kingdom laws, decrees or regulations affecting the remittance of
dividends or other payments to holders of Registrant's Ordinary Shares who are non-residents of the
United Kingdom, except as outlined in (k) below.
(j) United Kingdom Tax Effects on United States Owners.
United Kingdom taxes will be assessed and withheld from participants who are considered United
States residents ("U.S. Participants"). U.S. Participants are generally not subject to United
Kingdom capital gains tax or United Kingdom inheritance tax.
A sale of Ordinary Shares by a U.S. Participant is subject to United Kingdom stamp duty, or
stamp duty reserve tax ("SDRT"), as applicable. The minimum stamp duty liability is five pounds
Sterling (L5). Currently, SDRT is assessed at a rate of 0.5% of the purchase price.
(k) Reciprocal Tax Treaties Affecting Withholding.
None.
Item 5. Interests of Named Experts and Counsel
None.
Item 6. Indemnification of Directors and Officers
English law does not permit a company to indemnify a director or an officer of the company against
any liability which by virtue of any rule of law would otherwise attach to him in respect of
negligence, default, breach of duty or breach of trust in relation to the company. However, English
law does permit a company to purchase insurance for its directors and officers against such
liabilities. In addition, a company may exempt or indemnity a director or officer against any
liability to a third party, or indemnify a director or officer acting as a trustee of an
occupational pension scheme against liability incurred in connection with the company's activities
as trustee of the scheme, but only in the event that such liability is incurred by such director or
officer in defending any legal proceeding (whether civil or criminal) in which judgment is given in
his favor or in which
Table of Contents
he is acquitted or in certain instances where, although he is liable, a court
finds such director or officer acted honestly and reasonably and that having regard to all the
circumstances he ought fairly to be excused and relief is granted by the court.
Item 7. Exemption From Registration Claimed
Not applicable.
Item 8. Exhibits.
3.1
Memorandum and Articles of Association of GlaxoSmithKline plc
(incorporated by reference to Exhibit No. 1.1 of the Annual Report on Form 20-F
of GlaxoSmithKline plc, for the year ended December 31, 2008).
4.1
Deposit Agreement among GlaxoSmithKline plc and The Bank of New
York, as Depositary, and the holders from time to time of the American Depositary
Receipts issued thereunder, including the form of American Depositary Receipt
(incorporated by reference to Registration Statement on Form F-6, Registration
No. 333-148017).
4.2
GlaxoSmithKline Retirement Savings Plan (incorporated by reference
to Exhibit No. 4.6 of the Registration Statement of GlaxoSmithKline plc on Form
S-8, Registration No. 333-13022).
4.3
Amendment No. 1 to GlaxoSmithKline Retirement Savings Plan.
4.4
Amendment No. 2 to GlaxoSmithKline Retirement Savings Plan.
4.5
Amendment No. 3 to GlaxoSmithKline Retirement Savings Plan.
4.6
GSK Puerto Rico Retirement Savings Plan (incorporated by reference
to Exhibit No. 4.9 of the Registration Statement of GlaxoSmithKline plc on Form
S-8, Registration No. 333-13022).
4.7
Amendment No. 1 to GSK Puerto Rico Retirement Savings Plan.
4.8
Amendment No. 2 to GSK Puerto Rico Retirement Savings Plan.
4.9
Amendment No. 3 to GSK Puerto Rico Retirement Savings Plan.
4.10
GlaxoSmithKline 2009 Share Option Plan.
4.11
GlaxoSmithKline 2009 Performance Share Plan.
4.12
GlaxoSmithKline 2009 Share Value Plan.
4.13
GSK Research & Development Employee Inventor Award Programme
5.1
Opinion of Linklaters.
5.2
Opinion of Pepper Hamilton LLP.
23.1
Consent of PricewaterhouseCoopers (filed herewith).
23.2
Consent of Linklaters (contained in Exhibit 5.1).
24.1
Power of Attorney (contained in the signature pages hereto).
Table of Contents
Item 9 Undertakings.
Item 512(a) of Regulation S-K
The undersigned Registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-effective
amendment to this Registration Statement:
(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of
1933, as amended (the "Securities Act");
(ii) To reflect in the prospectus any facts or events arising after the effective date
of the registration statement (or the most recent post-effective amendment thereof) which,
individually or in
the aggregate, represent a fundamental change in the information set forth in the
registration statement. Notwithstanding the foregoing, any increase or decrease in volume of
securities offered (if the total dollar value of securities offered would not exceed that
which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule
424(b) if, in the aggregate, the changes in volume and price represent no more than a 20%
change in the maximum aggregate offering price set forth in the "Calculation of Registration
Fee" table in the effective registration statement;
(iii) To include any material information with respect to the plan of distribution not
previously disclosed in this Registration Statement or any material change to such
information in this Registration Statement;
provided
,
however
, that paragraphs (1)(i) and (1)(ii) above do not apply if
the information required to be included in a post-effective amendment by those paragraphs is
contained in reports filed with or furnished to the Commission by the Registrant pursuant to
Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration
Statement.
(2) That, for the purpose of determining any liability under the Securities Act each such
post-effective amendment shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof; and
(3) To remove from registration by means of a post-effective amendment any of the securities
being registered which remain unsold at the termination of the offering.
Item 512(b) of Regulation S-K
The undersigned Registrant hereby undertakes that, for purposes of determining any liability
under the Securities Act each filing of the Registrant's annual report pursuant to Section 13(a) or
Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's
annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in
the registration statement shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time shall be deemed to be
the initial bona fide offering thereof.
Table of Contents
Item 512(h) of Regulation S-K.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted
to directors, officers and controlling persons of the Registrant pursuant to the foregoing
provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such
indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than
the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered,
the Registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue.
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it
has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and
has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the Commonwealth of Pennsylvania, on October 28, 2009.
GLAXOSMITHKLINE PLC
/s/ William J. Mosher
William J. Mosher, Authorized U.S. Representative
POWER OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes
and appoints William J. Mosher, Victoria A. Whyte and Justin T. Huang (with full power to each of
them to act alone) his or her true and lawful attorney-in-fact and agent, with full power of
substitution and resubstitution, for him or her and in his or her name, place and stead, in any and
all capacities, to sign any and all amendments (including post-effective amendments) to this
registration statement, and to file the same, with exhibits thereto, and other documents in
connection therewith, with the Securities and Exchange Commission, granting unto said
attorney-in-fact and agent full power and authority to do and perform each and every act and thing
requisite and necessary to be done, as fully to all intents and purposes as he or she might or
could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or
either of them, or their or his or her substitute or substitutes, may lawfully do or cause to be
done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been
signed below by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Sir Christopher Gent
Chairman; Director
October 1, 2009
Sir Christopher Gent
/s/ Andrew Witty
Chief Executive Officer; Director
October 1, 2009
Andrew Witty
/s/ Professor Sir Roy Anderson
Director
October 1, 2009
Professor Sir Roy Anderson
Table of Contents
Signature
Title
Date
/s/ Dr. Stephanie Burns
Director
October 1, 2009
Dr. Stephanie Burns
/s/ Lawrence Culp
Director
October 1, 2009
Lawrence Culp
/s/ Sir Crispin Davis
Director
October 1, 2009
Sir Crispin Davis
/s/ Tom de Swaan
Director
October 1, 2009
Tom de Swaan
/s/ Julian Heslop
Chief Financial Officer; Director
October 1, 2009
Julian Heslop
/s/ Sir Deryck Maughan
Director
October 1, 2009
Sir Deryck Maughan
/s/ James Murdoch
Director
October 1, 2009
James Murdoch
/s/ Dr. Daniel Podolsky
Director
October 1, 2009
Dr. Daniel Podolsky
/s/ Dr. Moncef Slaoui
Chairman Research & Development;
October 1, 2009
Dr. Moncef Slaoui
Director
/s/ Sir Robert Wilson
Director
October 1, 2009
Sir Robert Wilson
Table of Contents
EXHIBIT INDEX
Exhibit
Exhibit
Number
Description
4.3
Amendment No. 1 to GlaxoSmithKline Retirement Savings Plan.
4.4
Amendment No. 2 to GlaxoSmithKline Retirement Savings Plan.
4.5
Amendment No. 3 to GlaxoSmithKline Retirement Savings Plan.
4.7
Amendment No. 1 to GSK Puerto Rico Retirement Savings Plan.
4.8
Amendment No. 2 to GSK Puerto Rico Retirement Savings Plan.
4.9
Amendment No. 3 to GSK Puerto Rico Retirement Savings Plan.
4.10
GlaxoSmithKline 2009 Share Option Plan.
4.11
GlaxoSmithKline 2009 Performance Share Plan .
4.12
GlaxoSmithKline 2009 Share Value Plan.
4.13
GSK Research & Development Employee Inventor Award Programme
5.1
Opinion of Linklaters.
5.2
Opinion of Pepper Hamilton LLP.
23.1
Consent of Pricewaterhouse Coopers LLP.
23.2
Consent of Linklaters (contained in Exhibit 5.1).
24.1
Power of Attorney (contained in the signature pages hereto).